Abstract

Vascular and traumatic injuries of the central nervous system are recognized as global health priorities. A polypharmacology approach that is able to simultaneously target several injury factors by the combination of agents having synergistic effects appears to be promising. Herein, we designed a polymeric delivery system loaded with two drugs, ibuprofen (Ibu) and thyroid hormone triiodothyronine (T3) to in vitro release the suitable amount of the anti-inflammation and the remyelination drug. As a production method, electrospinning technology was used. First, Ibu-loaded micro (diameter circa 0.95–1.20 µm) and nano (diameter circa 0.70 µm) fibers were produced using poly(l-lactide) PLLA and PLGA with different lactide/glycolide ratios (50:50, 75:25, and 85:15) to select the most suitable polymer and fiber diameter. Based on the in vitro release results and in-house knowledge, PLLA nanofibers (mean diameter = 580 ± 120 nm) loaded with both Ibu and T3 were then successfully produced by a co-axial electrospinning technique. The in vitro release studies demonstrated that the final Ibu/T3 PLLA system extended the release of both drugs for 14 days, providing the target sustained release. Finally, studies in cell cultures (RAW macrophages and neural stem cell-derived oligodendrocyte precursor cells—OPCs) demonstrated the anti-inflammatory and promyelinating efficacy of the dual drug-loaded delivery platform.

Highlights

  • Detailed analysis of the problem led us to formulate the hypothesis that coadministration of Ibu and T3 at the lesion site by a local delivery platform may simultaneously contrast neuroinflammation and induce remyelination via oligodendrocyte maturation, with enhanced therapeutic efficacy

  • Tissue inflammation has been demonstrated to block the terminal differentiation of oligodendrocyte precursor cells (OPCs), the cells responsible for myelin repair [16,20]

  • The key to developing efficient treatments is to minimize the detrimental effects of neuroinflammation while promoting the beneficial ones, and at the same time, to create optimal conditions for regeneration and repair after injury [21]

Read more

Summary

Introduction

Acute lesions of the central nervous system (CNS) due to vascular and traumatic events are increasingly recognized as global health priorities because of their incidence, Pharmaceutics 2021, 13, 848. Pharmaceutics 2021, 13, 848 resulting in chronic disabilities, and consequent individual, medical, and social costs. 50% of survivors experience chronic disabilities [1]. In 2016, 27.08 million new cases of traumatic brain injuries (TBIs) and 0.93 million cases of spinal cord injuries (SCIs) have been registered worldwide, constituting a considerable proportion of the global injury burden [2]. A single brain injury can accelerate or precipitate age-related neurodegenerative diseases, including. Alzheimer’s disease, Parkinson’s disease, and motor neuron disease, and repetitive mild traumatic brain injuries can provoke the development of a tauopathy and chronic traumatic encephalopathy. Neurological, cognitive, and psychiatric sequelae are quite common, strongly impacting quality of life [3]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call